AEON Biopharma

AEON on NYSEAmerican. Market value $8m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 22 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

10 investors own more than 5%.

  • Daewoong Pharmaceutical Co. Ltd ("DWP")
    Strategic holder
    49.8%+49.5 pts
    Since 21 January 2026
    What they said

    The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. DWC is a shareholder of DWP with 52% of shares outstanding. DWP is the counterparty to the Issuer's license agreements for License & Supply Agreement, effective as of December 20, 2019,…

    Read the filing
  • Daewoong Co., Ltd.
    Passive investor
    at least 30.6%−19.4 pts
    (filed with 1 related holder)
    Since 30 October 2026
    What they said

    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The exercise of the Pre-Funded Warrants described in Item 3 was effected in accordance with the terms of the Pre-Funded Warrants. Except as described in this Amendment, the Reporting Persons…

    Read the filing
  • Timothy P. Lynch
    Passive investor
    13.0%
    Since 19 August 2026
  • at least 10.0%
    (filed with 2 related holders)
    Since 30 September 2026
  • Ikarian Capital, LLC
    Passive investor
    at least 9.9%
    (filed with 1 related holder)
    Since 30 September 2026
  • at least 9.9%
    (filed with 3 related holders)
    Since 15 July 2026
  • Chernett Jorey
    Passive investor
    9.9%
    Since 27 May 2025
  • Since 26 February 2025
  • Bigger Michael
    Passive investor
    at least 6.1%
    (filed with 6 related holders)
    Since 6 January 2025
  • Robert J Palmisano
    Insider or founder
    at least 5.7%0.0 pts
    (filed with 1 related holder)
    Since 25 July 2024
  • L1 Capital Global Opportunities Master Fund, Ltd.
    Passive investor
    Sold down below 5%
    Since 31 March 2025
  • Sold down below 5%
    Since 31 December 2024
  • Alta Partners LLC
    Passive investor
    Sold down below 5%
    Since 30 September 2025
  • Sold down below 5%
    Since 31 March 2025
  • S.H.N. Financial Investments Ltd.
    Passive investor
    Sold down below 5%
    Since 31 March 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $57,054 of shares on the open market.

Cluster buy3 insiders bought within 30 days (19 November 2026 to 20 November 2026).
  • Wilson Alexander Blair
    CLO, CSO and Corp Secretary
    Bought
    Date
    20 November 2026
    Shares
    135,706
    Price
    $0.13
    Value
    $17,479
  • Bancroft Robert E.
    President and CEO, Director
    Bought
    Date
    19 November 2026
    Shares
    152,333
    Price
    $0.13
    Value
    $19,590
  • Sy Jennifer
    Chief Accounting Officer
    Bought
    Date
    19 November 2026
    Shares
    153,846
    Price
    $0.13
    Value
    $19,985

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in AEON Biopharma’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 12 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued.”
    Show the full paragraph
    The commencement of additional studies, preparation for future FDA meetings and any further development or commercialization of ABP-450 would require additional funding in the form of equity financings or debt. There can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be commercially acceptable. Furthermore, the use of equity as a source of financing would dilute existing stockholders. The Company currently expects its existing cash and cash equivalents to fund operations into the second quarter of 2027, which is less than one year from the date these condensed consolidated financial statements are issued. As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued.

    From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

A big holder just moved. The deep dive shows what the business is worth.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.